The GG COVID-19 variant Kit (GG COV-VOC-01; NOT AVAILABLE IN THE US, approved for export and use in Europe and Asia) was designed to detect clinically significant genetic mutations based on the genomic database of COVID-19. Laboratories supported by the US government have doubled the rate at which they are sequencing SARS-CoV-2 genomes over the past two months. However, we still don’t know how many COVID-19 variants there are exactly in the United states as US doesn’t have a single health system for COVID-19 surveillance.
The GG COVID-19 mutation kit enables multiplexing mutation hot spots to detect most of the current COVID-19 variants of interest/concern including the “Indian mutant”. COVID variants may be more transmissible, susceptible to “vaccine escape”, or be missed by regular COVID-19 testing methods such as Real time PCR, antigen, or rapid testing.
GG COVID-19 mutation kit is versatile, can be run on a variety of different sequencers with a running time of ~2 hour (minus the nucleic acid extraction time) to be used in the in vitro qualitative detection of COVID-19 virus mutation from clinical specimens including nasopharyngeal, oropharyngeal, and lower respiratory specimens such as sputum.
We have 3 types of mutant kits
- Real Time PCR kit
- Single Tube, Omicron/Delta variant type real-time PCR Kit, 4-plex (Can differentiate Delta / Omicron/ non-delta/non-Omicron variant) (GG-COV-O/D-01/ GG-COV-O-02)
- Double Tube, 4-plex Real Time PCR Kit (Can differentiate Delta/ Delta plus/ Omicron/ non-delta/non-Omicron variant accurately) (GG-COV-VOC2-01)
- Triple Tube, 4-Plex Real Time PCR Kit of 6 VOCs (alpha, beta, gamma, delta, delta plus, kappa, non-VOC variant) (GG-COV-VOC1-01)
- Covid mutant all type SNaPshot kit (minisequencing) (GG-SNP-01)
- Covid mutant all type DNA Microarray (GG-COV-APX-01)
: APEX DNA chip
The GG COVID-19 variant Kit (GG-VOC1-01/2) allows differentiation of the Alpha (B.1.1.7), Beta (B.1.351)/ Gamma (P.1), Delta (B.1.617.2.) Kappa (B.1.617.1), Lambda (C.37), Eta (B.1.525)/Mu (B.1.621) and Omicron (B.1.1.529) as well as differentiation of Omicron stealtj (BA.2) through Real-time RT-PCR in 2 -3 tubes. While both targeted sequencing and RT-PCR approaches enable viral evolution tracking, GG COVID-19 variant Kit offers a clear advantage: it can save time and money and is easy to use. This allows the assay to remain robust in the face of continual viral evolution. Cellgenmedix’s RT-PCR for SARS-CoV-2 variant testing has multiple probes targeting different regions of the viral genome, and has the capacity to detect all the variants of concern and interest in a very cost-effective format. Probes for each new loci is guaranteed to be developed within 2-4 weeks.
Our technology uses special probe which has the following advantages
Requiring little optimization and great flexibility for the new mutations that come out as COVID-19 progresses
High throughput level and applicability
For collaboration contact:
For Research Use Only. Not for use in diagnostic procedures to date.